BiotechTube

NBI-98854 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tourette Syndrome

Conditions

Tourette Syndrome

Trial Timeline

Mar 23, 2016 → Apr 14, 2017

NCT ID
NCT02679079

About NBI-98854 + Placebo

NBI-98854 + Placebo is a phase 2 stage product being developed by Neurocrine Biosciences for Tourette Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02679079. Target conditions include Tourette Syndrome.

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02679079Phase 2Completed
NCT02581865Phase 2Completed
NCT02274558Phase 3Completed

Competing Products

12 competing products in Tourette Syndrome

See all competitors
ProductCompanyStageHype Score
AZD5213 and placeboAstraZenecaPhase 2
35
PF-03654746 + Placebo + Placebo + PF-03654746PfizerPhase 2
27
AripiprazoleBristol Myers SquibbPre-clinical
18
NBI-98854Neurocrine BiosciencesPhase 2
24
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
24
ValbenazineNeurocrine BiosciencesPhase 2
32
NBI-98854Neurocrine BiosciencesPhase 1
26
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
32
ValbenazineNeurocrine BiosciencesPhase 2
32
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
32
Abobotulinum toxin AIpsenPre-clinical
19
Tetrabenazine MR + PlaceboBausch HealthPhase 2
21